Unless it was an exclusion criteria then no. They would certainly have to tell the investigators what drugs they are taking, but other than that they could be on a GLP-1 agonist.
Normally other drugs wash out in the randomisation, but when a totally new treatment enters the population then things can go wrong. Many Phase 3 trials have been upended by the GLP-1 agonists in the last few years.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable